ASLN Key Statistics, Chart & Performance
The current stock price of ASLN is 0.6 USD. In the past month the price decreased by -75.97%. In the past year, price decreased by -97.26%.
ASLN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.76B |
Related stock screener links
About ASLN
Company Profile
Aslan Pharmaceuticals Ltd is a SG-based company operating in Biotechnology industry. ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The firm's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. The company is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The firm is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The firm is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.
Company Info
ASLAN Pharmaceuticals Ltd
83 Clemenceau Avenue, #12-03 UE Square
Singapore 239920 SG
CEO: Carl Firth
Employees: 34
Phone: 6562224235
ASLAN Pharmaceuticals Ltd / ASLN FAQ
What does ASLN do?
Aslan Pharmaceuticals Ltd is a SG-based company operating in Biotechnology industry. ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The firm's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. The company is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The firm is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The firm is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.
What is the stock price of ASLAN Pharmaceuticals Ltd today?
The current stock price of ASLN is 0.6 USD. The price decreased by -14.27% in the last trading session.
Does ASLN stock pay dividends?
ASLN does not pay a dividend.
What is the ChartMill rating of ASLAN Pharmaceuticals Ltd stock?
ASLN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about ASLAN Pharmaceuticals Ltd (ASLN) stock?
8 analysts have analysed ASLN and the average price target is 77.52 USD. This implies a price increase of 12820% is expected in the next year compared to the current price of 0.6.
What is the ownership structure of ASLAN Pharmaceuticals Ltd (ASLN)?
You can find the ownership structure of ASLAN Pharmaceuticals Ltd (ASLN) on the Ownership tab.
ASLN Technical Analysis
ASLN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ASLN. ASLN has a bad profitability rating. Also its financial health evaluation is rather negative.
ASLN Financial Highlights
Over the last trailing twelve months ASLN reported a non-GAAP Earnings per Share(EPS) of -11.15. The EPS decreased by -173.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -93.07% | ||
| ROE | -806.53% | ||
| Debt/Equity | 3.84 |
ASLN Forecast & Estimates
8 analysts have analysed ASLN and the average price target is 77.52 USD. This implies a price increase of 12820% is expected in the next year compared to the current price of 0.6.
For the next year, analysts expect an EPS growth of 58.45% and a revenue growth -100% for ASLN